Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

60 DEGREES PHARMACEUTICALS, INC.

  • WASHINGTON, District of Columbia
  • Public · NASDAQ: SXTP
  • 3 employees
$3.8MMarket cap
$1.0MRevenue · FY2025
-$7.4MNet income
3Employees
SXTPNASDAQ
2023IPO

About 60 DEGREES PHARMACEUTICALS, INC.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$1.0M
Net income
-$7.4M
Total assets
$5.4M
Market cap
$3.8M

Source: SEC EDGAR · updated Jun 8, 2026

NASDAQ: SXTP

15-minute delayed · data by Polygon.io

Market cap
$3.8M
Open
Day range
Prev close
Volume
IPO date
Jul 12, 2023

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review 60 DEGREES PHARMACEUTICALS, INC..

Write a review
Explore

Similar companies

Browse all →